A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors
Latest Information Update: 03 Sep 2024
At a glance
- Drugs NDI-101150 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Nimbus Therapeutics
- 04 Jun 2024 Results of dose-escalation/expansion data as of Dec 13, 2023, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 23 May 2024 According to a Nimbus Therapeutics media release, data from the study will be presented as a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 June 4, 2024 in Chicago, IL.
- 23 May 2024 Results (n=59,as of March 18, 2024) presented in the Nimbus Therapeutics Media Release.